OVARIAN UNDIFFERENTIATED CARCINOMA
Clinical trials for OVARIAN UNDIFFERENTIATED CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new OVARIAN UNDIFFERENTIATED CARCINOMA trials appear
Sign up with your email to follow new studies for OVARIAN UNDIFFERENTIATED CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo shows promise in Hard-to-Treat ovarian cancer
Disease control OngoingThis study tests whether adding the experimental drug AZD1775 to standard chemotherapy (gemcitabine) can help women with ovarian, fallopian tube, or peritoneal cancer that has returned after platinum-based treatment. The drug works by blocking a protein that cancer cells use to r…
Matched conditions: OVARIAN UNDIFFERENTIATED CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 01, 2026 15:39 UTC
-
Measles virus hitches ride on stem cells to attack returning ovarian cancer
Disease control OngoingThis study tests a new way to treat ovarian, fallopian tube, or peritoneal cancer that has come back after standard treatments. Doctors take stem cells from fat tissue, infect them with a specially modified measles virus, and inject them into the abdomen. The stem cells carry the…
Matched conditions: OVARIAN UNDIFFERENTIATED CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Apr 30, 2026 15:50 UTC
-
New combo tackles tough ovarian cancers
Disease control OngoingThis early-phase trial tests a new drug (peposertib) combined with standard chemotherapy (PLD) for ovarian and related cancers that no longer respond to platinum-based treatments. The goal is to find the safest dose and see if the combination works better than chemo alone. About …
Matched conditions: OVARIAN UNDIFFERENTIATED CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 30, 2026 15:49 UTC
-
New drug combo could replace chemo for recurrent ovarian cancer
Disease control OngoingThis study tests whether the drugs olaparib and cediranib, alone or together, work better than standard chemotherapy for women with ovarian, fallopian tube, or peritoneal cancer that has returned after initial treatment. About 579 women with platinum-sensitive cancer are particip…
Matched conditions: OVARIAN UNDIFFERENTIATED CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 29, 2026 15:01 UTC